Synergy Healthcare plc : Sellers pressure likely to dominate
Entry price | Target | Stop-loss | Potential |
---|
GBX 1,409 |
GBX 0 |
GBX 1,490 |
+100% |
---|
Synergy Healthcare could start a technical downward trend after the rebound in recent sessions.
Fundamentals on the company are strong as shown by the Surperformance ratings. However, the analysts’ consensus is mixed and their average target price offers no potential for the stock. In facts, the target is 7% lower than current prices.
From a technical viewpoint, the proximity of the GBp 1430 medium-term resistance limits the upside potential on the stock. The uptrend in the short term could be stopped by this level and prices could decrease sharply in the coming sessions. Technical indicators also show an overbought situation that reinforces this bearish scenario. Thus, there is a higher downside potential than upside.
Due to the technical configuration and a bad fundamental situation that does not justify the current valuation of the group, investors can open a short position close to the GBp 1430 resistance. The price target is set at GBp 1310 and a stop loss will be placed above GBp 1430.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.